Abstract: The invention relates to three isolated DNA molecules that encode for proteins, BigL1, BigL2 and BigL3, in the Leptospira sp bacterium which have repetitive Bacterial-Ig-like (Big) domains and their use in diagnostic, therapeutic and vaccine applications. According to the present invention, the isolated molecules encoding for BigL1, BigL2 and BigL3 proteins are used for the diagnosis and prevention of infection with Leptospira species that are capable of producing disease in humans and other mammals, including those of veterinary importance.

Abstract: The invention relates to three isolated DNA molecules that encode for proteins, BigL1, BigL2 and BigL3, in the Leptospira sp bacterium which have repetitive Bacterial-Ig-like (Big) domains and their use in diagnostic, therapeutic and vaccine applications. According to the present invention, the isolated molecules encoding for BigL1, BigL2 and BigL3 proteins are used for the diagnosis and prevention of infection with Leptospira species that are capable of producing disease in humans and other mammals, including those of veterinary importance.

Abstract: A system and method for Multifractal-Detrended Fluctuation Analysis (MF-DFA) on digitized Human EEG signals is presented. A list of Hurst exponents, or Hurst exponent spectrum (“h” values) are generated, and multifractal singularity spectrum indices (“D(h)” values) produce a graph that approximates an inverted parabola. The output multifractal DFA spectrum is able to represent key features of the internal neuronal dynamics for the cortical neurons underlying the scalp-placed electrode which records the signals.

Abstract: Compositions and methods for diagnosis or treatment of epilepsy disease with EFHC1, EFHC1 agonists, or EFHC1 analogs are provided. Compositions and methods for diagnosis or treatment of epilepsy disease with EFHC1a, EFHC1a agonists, or EFHC1a analogs are provided.

Abstract: The disclosure relates to methods of preserving or improving microvascular integrity in a patient in need thereof comprising administering pirfenidone therapy to the patient.

Abstract: The present invention provides methods for preventing, attenuating neuronal damage or stimulating neuronal repair prior or following central nervous system injury.

Abstract: The present invention provides methods for restoring or enhancing T cell mediated immune response in individuals of middle and advanced age.

Abstract: The present application is related to compounds which are novel neurotrophin mimetics. The application also discloses the treatment of disorders associated with p75 expression, such as degradation or dysfunction of cells expressing p75 in a mammal by administering an effective amount of such compounds.

Abstract: The present invention provides methods for restoring or enhancing T cell mediated immune response in individuals of middle and advanced age.

Abstract: The inventors have discovered a collection of proteinaceous biomarkers (“AD biomarkers) which can be measured in peripheral biological fluid samples to aid in the diagnosis of neurodegenerative disorders, particularly Alzheimer's disease and mild cognitive impairment (MCI). The invention further provides methods of identifying candidate agents for the treatment of Alzheimer's disease by testing prospective agents for activity in modulating AD biomarker levels.

Abstract: Natural human autoantibodies against toxic assemblies of A? and related peptide species offer a unique immune repertoire. Based on this repertoire, the present invention provides compositions and methods for diagnosis as well as for prophylactic and therapeutic treatment of neurodegenerative diseases such as Alzheimer's disease that are characterized by accumulation of beta-amyloid deposits. The same human autoantibodies may be useful for prophylactic and therapeutic treatment of other neurodegenerative disorders and systemic pathological conditions that are due to or are associated with toxic assemblies of other amyloidogenic peptides or proteins.

Abstract: Described are probes and methods for detecting pathogens and antibiotic resistance of a specimen. The method comprises contacting the specimen with a growth medium; and lysing the specimen to release nucleic acid molecules from the specimen. The lysate of the specimen is contacted with a capture probe immobilized on a substrate, wherein the capture probe comprises an oligonucleotide that specifically hybridizes with a first target nucleic acid sequence region of ribosomal RNA. The lysate is in contact with a detector probe that comprises a detectably labeled oligonucleotide that specifically hybridizes with a second target nucleic acid sequence region of ribosomal RNA. The presence or absence of labeled oligonucleotide complexed with the substrate is determined. Detection of labeled oligonucleotide complexed with the substrate is indicative of the presence of pathogen. Performing the method in the presence and absence of an antibiotic permits detection of antibiotic resistance.

Abstract: Described is a method for modulating the phenotype of a cell, and particularly, of a target cell in a patient who has or is at risk of developing a disease or condition in which is associated with dysregulation of cellular phenotype. The method includes administration of a recombinant nucleic acid molecule encoding a protein having CREB biological activity or dominant negative CREB biological activity to a patient, in such a manner that the protein is expressed in a target cell of a patient and is sufficient to modulate the phenotype of the target cell. Such a method is particularly useful in patients who have, or at risk of developing, diabetes, obesity, macrovascular disease, heart failure, osteoarthritis, and neural diseases and conditions.